

BROOKS LABORATORIES LIMITED

CIN NO: L24232HP2002PLC000267

Tel No : +91 1795 654001/02/03, Fax No : +91 1795 236939, E-mail : investors@brookslabs.net, Website: www.brookslabs.net
 Unaudited Financial Results for the Quarter and Nine Month Ended December 31, 2015

PART I

(Rs. In lacs)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	(Unaudited)			(Unaudited)		(Audited)
1 Income from operations						
(a) Net sales (Net of excise duty)	2,086.73	2,047.17	2,368.19	5,931.60	6,169.91	8,521.33
Total income from operations (net)	2,086.73	2,047.17	2,368.19	5,931.60	6,169.91	8,521.33
2 Expenses						
(a) Cost of materials consumed	1,390.12	1,361.99	1,651.41	4,011.12	4,371.48	6,041.14
(b) Changes in inventories of finished goods & work-in-progress	(16.93)	(7.75)	22.06	4.91	48.84	23.61
(d) Employee benefits expense	185.38	187.18	124.04	503.60	353.01	474.67
(e) Depreciation and amortization expense	30.28	28.53	23.28	86.85	83.93	110.36
(f) Other Expenses	224.91	239.01	364.24	678.52	925.48	1,295.80
Total expenses	1,813.76	1,808.96	2,185.03	5,285.00	5,782.74	7,945.59
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	272.97	238.21	183.16	646.60	387.17	575.74
4 Other income	53.65	44.28	68.38	134.35	199.25	225.17
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	326.62	282.49	251.54	780.95	586.42	800.91
6 Finance costs	35.69	26.73	25.99	69.28	33.18	44.34
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	290.93	255.76	225.55	711.67	553.25	756.57
8 Exceptional items / Prior period items	-	-	0.00	-	(210.18)	278.47
9 Profit / (Loss) from ordinary activities before tax (7 - 8)	290.93	255.76	225.55	711.67	763.42	1,035.04
10 Tax expense (Refer Note 2)	11.47	85.60	46.78	110.68	50.93	88.32
11 Net Profit / (Loss) from ordinary activities after tax (9-10)	279.46	170.16	178.77	600.99	712.49	946.72
12 Extraordinary items	-	-	-	-	-	-
13 Net Profit / (Loss) for the period (11 + 12)	279.46	170.16	178.77	600.99	712.49	946.72
14 Paid-up equity share capital (Face Value Rs.10/- per share)	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	9,523.04
16.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):						
(a) Basic -in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
(b) Diluted- in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
16.ii Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):						
(a) Basic -in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
(b) Diluted- in Rs.	1.73	1.05	1.10	3.71	4.40	5.85

Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2016.
- Tax expense includes Current Tax, Mat Credit Entitlement, Deferred Tax & Taxes for earlier years. Tax expense of Nine Month ended & for Quarter ended 30th September 2015 includes Rs 70.47 lacs for taxes of earlier Years.
- The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).
- Figures of the previous period / year have been reclassified/ regrouped wherever necessary.

Date : February 12, 2016
 Place : Mumbai

For and on behalf of the Board

Rajesh Mahajan
 DIN No. : 02000634
 Managing Director

